Acadia Pharmaceuticals is a biopharmaceutical company that focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. Its lead product candidate, NUPLAZID, has completed the Phase III pivotal trials for the treatment of Parkinson's disease, Phase II trial for the treatment of schizophrenia and Phase II study for the treatment of Alzheimer's disease. The company was founded in 1993 and is headquartered in San Diego, California.